| Elizabeth Ann Johnston, LPN | |
|
1051 Cumberland Ave, West Lafayette, IN 47906-1447 | |
| (765) 463-2571 | |
| Not Available |
| Full Name | Elizabeth Ann Johnston |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 1051 Cumberland Ave, West Lafayette, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215688148 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 27039913A (Indiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Ann Johnston, LPN 1425 W Candlewick Ln, West Lafayette, IN 47906-7110 Ph: (765) 412-4649 | Elizabeth Ann Johnston, LPN 1051 Cumberland Ave, West Lafayette, IN 47906-1447 Ph: (765) 463-2571 |
News Archive
A new study in monkeys, published on October 14, 2019, in the Proceedings of the National Academy of Sciences, shows that organisms at the bottom of the social hierarchy live shorter lives. Moreover, they experience more sickness, and may continue to experience health problems despite moving up later. Adverse experiences of social life continue to reflect in their genes much longer than the actual experience, in the form of changes in gene expression via altered gene regulation.
Although endocrine therapy for breast cancer has shown excellent results in controlling the disease, responsiveness to the therapy depends on whether or not there is expression of estrogen receptors in breast cancer cells. Research from the Sbarro Institute for Cancer Research and Molecular Medicine, a nonprofit cancer, cardiovascular and diabetes research center located in Philadelphia, PA, reports on the effectiveness of a new molecule, Scriptaid, that restores receptivity to endocrine therapy in breast cancer cell lines that had tested negative for the expression of estrogen receptors.
Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy (ipilumumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor.
Imagine a chip, strategically placed in the brain, that could prevent epileptic seizures or allow someone who has lost a limb to control an artificial arm just by thinking about it.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
› Verified 4 days ago
Jessie Villarreal, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1051 Cumberland Ave, West Lafayette, IN 47906 Phone: 765-414-9569 | |
Michele Spray, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3851 N River Rd, West Lafayette, IN 47906 Phone: 765-463-6302 |